Fluticasone/salmeterol: labeling change
Prescrire international 17(98): 229
2008
ISSN/ISBN: 1167-7422 PMID: 19418648 Document Number: 620536
The fixed-dose combination of fluticasone and salmeterol has no place in the treatment of asthma or chronic obstructive pulmonary disease (COPD).
Document emailed within 1 workday
Related Documents
Maneechotesuwan, K.; Assawabhumi, J.; Rattanasaengloet, K.; Suthamsmai, T.; Pipopsuthipaiboon, S.; Udompunturak, S. 2014: Comparison between the effects of generic and original salmeterol/fluticasone combination (SFC) treatment on airway inflammation in stable asthmatic patients Journal of the Medical Association of Thailand 97(Suppl 3): S91-100Stoloff, S.; Samuels, S.; Kerney, D.; Brown, C.P. 2006: Management of chronic obstructive pulmonary disease associated with chronic bronchitis with inhaled fluticasone propionate/salmeterol (ADVAIR DISKUS) 250/50: results of a patient experience trial Medgenmed: Medscape General Medicine 8(1): 86
Ringbaek, T.J.; Søes-Petersen, U.; Christensen, M.; Iversen, E.T.; Rasmussen, F.V. 1996: Salmeterol improves the control of disease in patients with moderate asthma. a comparative study of inhaled salmeterol 50 mg and salbutamol depot tablets 8 mg, both administered twice daily Ugeskrift for Laeger 158(27): 3940-3943
Kupryś-Lipińska, I.; Tworek, D.; Vanderbist, F.; Bocheńska-Marciniak, M.łg.; Kuna, P. 2013: Efficacy and safety of a 12-week therapy with a new formulation of fluticasone propionate at doses of 125 and 250 μg administered through a new generation cyclohaler twice daily, in comparison to fluticasone propionate 500 μg dry powder inhaler twice daily in patients with moderate asthma Pneumonologia i Alergologia Polska 81(6): 527-536
Sheffer, A.L.; LaForce, C.; Chervinsky, P.; Pearlman, D.; Schaberg, A. 1996: Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma. Fluticasone Propionate Asthma Study Group Journal of Family Practice 42(4): 369-375
Boutonnat, J.; Barbier, M.; Ronot, X.; Seigneurin, D. 2000: Nucleus labeling or membrane labeling for studying the proliferation of drug treated cells? Morphologie: Bulletin de l'Association des Anatomistes 84(265): 11-15
2014: Food labeling; nutrition labeling of standard menu items in restaurants and similar retail food establishments. Final rule Federal Register 79(230): 71155-71259
Apley, M.D. 1995: AHi perspectives: flexible drug labeling and its impact on the drug development process. Practical aspects of flexible labeling in feedlots Journal of the American Veterinary Medical Association 207(7): 901
Curran, M.A. 1994: Salmeterol in the treatment of asthma Australian Family Physician 23(10): 2038
Cayley, W.E. 2009: Should salmeterol be used for long-term asthma control? American Family Physician 79(11): 957
Van Dam, J.G. 1996: Salmeterol no longer banned in Olympic Games Nederlands Tijdschrift Voor Geneeskunde 140(31): 1612
Johnson, M. 1996: Fluticasone propionate: safety profile Cutis 57(2 Suppl): 10-12
Wrońska, J.; Chazan, R.; Mazurek, J.; Droszcz, W. 1998: Treatment with salmeterol and quality of life in patients with asthma Pneumonologia i Alergologia Polska 66(3-4): 193-197
Baughman, R.P.; Iannuzzi, M.C.; Lower, E.E.; Moller, D.R.; Balkissoon, R.C.; Winget, D.B.; Judson, M.A. 2002: Use of fluticasone in acute symptomatic pulmonary sarcoidosis Sarcoidosis Vasculitis and Diffuse Lung Diseases: Official Journal of Wasog 19(3): 198-204
English, J.; Greer, K.E.; McCrone, S.A.; Patterson, J.W.; VanLoock, J.S. 2003: Fluticasone-associated cutaneous allergic granulomatous vasculitis Journal of Drugs in Dermatology: Jdd 2(3): 326-329
Russell, G.; Williams, D.A.; Weller, P.; Price, J.F. 1995: Salmeterol xinafoate in children on high dose inhaled steroids Annals of Allergy Asthma and Immunology: Official Publication of the American College of Allergy Asthma and Immunology 75(5): 423-428
Hu, J.-g.; Jia, W.; Hu, X.-w.; Wang, Y. 2003: Effect of salmeterol on function of bronchi in pneumoconiosis of coal miners Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 21(3): 233-234
Słomka, A. 1997: Evaluation of the effectiveness and safety of salmeterol in children with nocturnal dyspnea Pneumonologia i Alergologia Polska 65(Suppl 1): 44-50
Robinson, D.S. 1994: Psychotropic drug labeling: regulatory, pharmaceutical industry, and clinical issues and perspectives. a pharmaceutical industry perspective on drug labeling Psychopharmacology Bulletin 30(1): 23-25
Piacquadio, D.J. 1996: Topical corticosteroids in clinical practice: focus on fluticasone propionate Cutis 57(2 Suppl): 4-9